Incyte Corporation (BVMF:I1NC34)

Market Cap	96.99B +23.7%
Revenue (ttm)	28.32B +21.2%
Net Income	7.09B +3,845.0%
EPS	35.31 +4,173.3%
Shares Out	n/a
PE Ratio	13.69
Forward PE	12.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	87
Open	243.25
Previous Close	n/a
Day's Range	242.50 - 243.25
52-Week Range	170.00 - 299.88
Beta	n/a
RSI	34.18
Earnings Date	Apr 28, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,844
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: I1NC34

Financial Performance

In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.

Financial numbers in USD